-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Reinstates Neutral on NovoCure, Announces $17 Price Target

Benzinga·07/13/2026 11:09:22
Listen to the news
JP Morgan analyst Jessica Fye reinstates NovoCure (NASDAQ:NVCR) with a Neutral and announces $17 price target.